PAZ Arzneimittelentwicklungsgesellschaft mbH

PAZ, headquartered in Frankfurt and with further offices in Germany, specializes in the development, patenting and out-licensing of innovative drugs based on known active ingredients. The company's main activity is the development of NCEs based on pure enantiomers of known racemic active ingredients. Dexibuprofen, the dextrorotatory enantiomer of ibuprofen, was the first such product to be developed in collaboration with a licensee and has so far been launched in 26 countries as an analgesic and anti-inflammatory drug. The main active ingredient of PAZ is tarenflurbil, which is licensed to Nitec Pharma. Based on the newly discovered mechanisms of action for this class of compounds, the suitability of tarenflurbil for other therapeutic applications besides use as an analgesic, anti-inflammatory drug is being evaluated. PAZ was founded in 1980 and is privately held as an independent company.